Call: +919821618106 goral@indonipponivf.com Book an Appointment
Circular teal and navy emblem logo for Indo Nippon IVF Indo Nippon IVF

Recurrent miscarriage after IVF: testing and next steps

Recurrent miscarriage after IVF can be emotionally and financially exhausting, particularly when serial pregnancy tests, scans and transfer appointments have given hopeful results. The experience may also be confusing because an early pregnancy loss after assisted reproduction does not necessarily indicate a laboratory failure. Chromosomal factors, uterine anatomy, immune-related conditions and other medical factors can all influence early pregnancy outcomes. Learn more about The Role Of Coenzyme Q10 In Improving Egg Quality A07861.

A useful review should separate confirmed clinical findings from tests that are routinely offered without strong evidence. The aim is not to investigate everything indiscriminately, but to identify factors that could change treatment before another IVF cycle. This is particularly important for Australians considering treatment in Mumbai or continuing care with a local fertility specialist after cross-border treatment. Learn more about 1apotekonline.com.

What recurrent miscarriage means

In Australian practice, miscarriage usually refers to a nonviable pregnancy before 20 weeks. A clinical miscarriage differs from a biochemical pregnancy, in which pregnancy hormone briefly rises but no gestational sac develops. Recurrent pregnancy loss, or recurrent miscarriage, commonly describes two or more clinical losses, although some clinics include biochemical losses when assessing recurrent pregnancy loss.

The most frequent cause of early miscarriage is a random chromosomal abnormality in the embryo or fetus, with risk increasing with maternal age. IVF does not eliminate this risk because an apparently normal embryo can still have an undetected chromosome error. Uterine abnormalities, antiphospholipid syndrome, poorly controlled thyroid disease or diabetes, and less commonly infections or inherited genetic rearrangements may also contribute.

Every previous outcome should be documented, including the gestational age, ultrasound findings, quantitative hCG results, pathology reports and whether an ectopic or molar pregnancy occurred. This information allows the specialist to distinguish a pattern of early clinical miscarriage from implantation failure or repeated biochemical pregnancies. Counselling and peer support can help patients process the losses while medical investigations proceed.

The medical assessment

A recurrent pregnancy loss review is best coordinated by a reproductive medicine specialist working with an obstetrician or a dedicated early-pregnancy clinic. A general practitioner can arrange referrals and provide continuity of care. In larger cities such as Sydney, Melbourne and Brisbane, patients can access hospital-based recurrent miscarriage services, private fertility specialists and specialist pathology providers, although waiting times and out-of-pocket costs vary.

The initial blood tests are selected according to the clinical history. They may include a full blood count, blood group and antibody screen, thyroid function, glucose or HbA1c, and targeted infection testing when symptoms or exposure suggest it. Ovarian reserve markers such as AMH, FSH and estradiol can help plan IVF treatment, but they do not explain why a pregnancy was lost.

Antiphospholipid antibody testing is particularly relevant when losses occur after a confirmed fetal heartbeat. The usual panel includes lupus anticoagulant, anticardiolipin antibodies and anti-beta-2 glycoprotein I antibodies. A positive result is generally confirmed on repeat testing at least 12 weeks later, and the pattern of results influences whether anticoagulant treatment is recommended. Broad autoimmune panels, commercial immune-cell assays, unvalidated clotting tests and routine endometrial receptivity testing are not supported as standard recurrent miscarriage investigations.

Genetic, uterine and embryo testing

Genetic counselling can help determine whether parental chromosome testing, previous pregnancy tissue testing or other genetic investigations would be useful. A peripheral blood karyotype may be recommended for one parent when there is a history of recurrent miscarriage, stillbirth, congenital abnormalities or a known family rearrangement. Testing tissue from a previous loss can sometimes identify a chromosome abnormality, but the result is less informative if no tissue was available or the testing was performed after the pregnancy had already resolved.

The uterine cavity should be assessed when the loss history, scan findings or IVF history suggest a structural cause. Transvaginal two-dimensional or three-dimensional ultrasound may identify a septum, polyps, fibroids or an abnormal contour. A saline infusion ultrasound or hysteroscopy can provide further detail when the cavity appears abnormal or the standard scan is inconclusive. Surgical treatment depends on the finding: removing a polyp differs from treating a fibroid or assessing a congenital uterine anomaly.

Ovarian function and embryo quality are separate considerations. CoQ10 and other supplements have been studied for ovarian response and egg quality rather than recurrent miscarriage prevention. This overview of Coenzyme Q10 egg quality explains its proposed antioxidant role, but current evidence does not justify using it as a substitute for genetic, uterine or medical assessment. Supplement strengths and interactions should also be reviewed with the treating clinician.

A practical review plan

Once the history and results are assembled, treatment should target confirmed findings. Confirmed obstetric antiphospholipid syndrome may require low-dose aspirin and heparin under specialist supervision, while thyroid or metabolic disorders should be treated to the recommended target. Progesterone can be considered in selected recurrent miscarriage cases, although evidence and guideline thresholds differ. Hysteroscopic surgery may be appropriate for certain polyps or other cavity abnormalities, while treatment of a uterine septum requires an individual fertility and obstetric assessment.

Medication access and quality deserve careful attention. Patients comparing prices for progesterone or supplements may encounter an online pharmacy source, but medicines purchased overseas may not meet Australian quality, supply or customs requirements. A local pharmacist should confirm the product, dose and prescription status, and any medicine used during conception or pregnancy should be TGA-approved and prescribed appropriately. Empirical anticoagulants, high-dose supplements or hormonal treatment without an indication may create more risk than benefit.

Before another cycle, ask the treating team to document the review and its proposed decision points.

This record should be shared with the specialist undertaking the next IVF cycle. It helps prevent repeated investigations while ensuring that previous results are genuinely considered in the new treatment plan.

IVF options and cross-border care

For Australians, cost can shape the next decision. Medicare generally does not subsidise IVF treatment, although eligible consultations and pathology may attract rebates. Private health insurance often includes a waiting period and may cover only part of the treatment, with exclusions for particular procedures. Patients should obtain written confirmation of benefits before committing to a long-distance treatment plan.

Mumbai has become an international centre for fertility treatment, and Indo Nippon IVF provides specialist fertility care, advanced laboratory technology and treatments including Mini IVF, ICSI, donor egg IVF, egg freezing, embryo transfer and pre-implantation genetic testing. The clinic also assists patients travelling from overseas. Results should still be compared using age-specific and treatment-specific live birth and miscarriage data rather than general clinic averages.

Travelling from Sydney, Melbourne or Brisbane involves long-haul flights, medication storage, time-zone changes and decisions about where follow-up and delivery care will occur. Prescription medicines, supplements and biological samples may be subject to Australian customs and TGA requirements, while pathology results obtained overseas may not transfer directly into an Australian medical record. A written summary of the IVF cycle, embryo transfer, medications and laboratory findings should therefore accompany the patient.

Cross-border care does not replace local obstetric supervision. Anyone considering donor eggs or surrogacy should obtain independent legal advice because the legal framework differs between Indian jurisdictions and Australian states. Commercial gestational surrogacy is prohibited in most Australian jurisdictions, while altruistic arrangements are permitted in some. An Australian fertility and obstetric team should be involved before treatment begins so that screening, pregnancy monitoring and delivery arrangements remain medically and legally coordinated.

Booking a focused fertility and miscarriage review

Patients who have experienced two or more pregnancy losses after IVF should request a dedicated recurrent miscarriage assessment before starting another cycle. Prepare a timeline of every transfer and loss, along with scans, pathology reports, medication records and previous fertility reviews. This information can help the specialist distinguish an isolated loss from a treatable pattern and avoid unnecessary repeat testing.

For a Mumbai-based consultation, contact Indo Nippon IVF and ask for a written plan covering investigations, proposed treatment, expected timing, medication supply and communication with the patient’s Australian clinician. A coordinated plan gives the patient clearer options for the next IVF cycle while keeping maternal health and early pregnancy care at the centre of the process.